United Kingdom-based AstraZeneca has revealed overall survival results from the Phase III FLAURA trial of Tagrisso (osimertinib) in the first line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC), it was reported yesterday.

Results indicated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint for Tagrisso compared to gefitinib or erlotinib, both of which were previous standard-of-care (SoC) treatments in this setting (HR 0.799 [95% CI, 0.641-0.997], p=0.0462).

The product delivered a median overall survival of 38.6 months versus 31.8 months for the comparator arm. At three years, 28% of patients in the Tagrisso arm and 9% of patients in the comparator arm remained on first-line study treatment. It also indicated a statistically significant and clinically meaningful 52% decrease in the risk of central nervous system disease progression, increasing the time patients with central nervous system metastases lived without central nervous system disease progression or death (HR 0.48 [95% CI, 0.26-0.86], p=0.014).

The results were presented at the Presidential Symposium of the ESMO (European Society for Medical Oncology) 2019 Congress in Barcelona, Spain (Abstract #LBA5_PR).